Literature DB >> 19148546

Polymorphisms of the ApoE, HSD3B1, IL-1beta and p53 genes are associated with the development of early uremic complications in diabetic patients: results of a DNA resequencing array study.

Dominika Szoke1, Bela Molnar, Norbert Solymosi, Karoly Racz, Peter Gergics, Bernadett Blasko, Barna Vasarhelyi, Adam Vannay, Yvette Mandy, Gergely Klausz, Zsofia Gyulai, Orsolya Galamb, Sandor Spisak, Bernadett Hutkai, Aniko Somogyi, Klara Berta, Andras Szabo, Tivadar Tulassay, Zsolt Tulassay.   

Abstract

Genetic polymorphisms of the genes involved in angiogenesis, the inflammatory cascade or apoptosis control can influence the chronic complications of diabetic patients. Parallel evaluation of multiple genetic polymorphisms became available with the development of DNA resequencing arrays. We aimed to develop a 16-gene, 18,859-nucleotide resequencing array to analyze the genetic background of uremic and gastrointestinal complications. DNA was isolated from 10 ml of peripheral blood of 41 non-uremic and 37 uremic patients with type II diabetes mellitus (DM); 32 suffering from gastric erosion complications. An Affymetrix Customseq Resequencing array was developed containing a total of 37 PCR products of selected genes. Confirmatory analysis was performed for 5 known polymorphisms by RFLP and for 4 others by capillary sequencing. Statistical analysis was performed using the Fisher's exact test. Correlations between the DNA resequencing array and the confirmatory methods were 96% for RFLP and 99.4% for capillary sequencing. The genetic polymorphisms of the ApoE, HSD3B1, IL-1beta and p53 genes were found to be significantly different (p<0.05) between the uremic and non-uremic diabetes group. In regards to the gastric erosion complications of the diabetic uremic patients, the A17708T polymorphism of the p53 intron 10 was found to have a statistically significant (p<0.05) role. In conclusion, DNA sequencing arrays can contribute to a multiparameter genetic analysis yielding highly correlating results using a single method in patients suffering type II DM.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19148546

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  6 in total

1.  Semantic integration of data on transcriptional regulation.

Authors:  Michael Baitaluk; Julia Ponomarenko
Journal:  Bioinformatics       Date:  2010-04-28       Impact factor: 6.937

Review 2.  The role of the p53 tumor suppressor in metabolism and diabetes.

Authors:  Che-Pei Kung; Maureen E Murphy
Journal:  J Endocrinol       Date:  2016-09-09       Impact factor: 4.286

3.  Identification of rare DNA variants in mitochondrial disorders with improved array-based sequencing.

Authors:  Wenyi Wang; Peidong Shen; Sreedevi Thiyagarajan; Shengrong Lin; Curtis Palm; Rita Horvath; Thomas Klopstock; David Cutler; Lynn Pique; Iris Schrijver; Ronald W Davis; Michael Mindrinos; Terence P Speed; Curt Scharfe
Journal:  Nucleic Acids Res       Date:  2010-09-15       Impact factor: 16.971

Review 4.  New technologies for the identification of novel genetic markers of disorders of sex development (DSD).

Authors:  A Bashamboo; S Ledig; P Wieacker; J C Achermann; J Achermann; K McElreavey
Journal:  Sex Dev       Date:  2010-07-03       Impact factor: 1.824

5.  Development of a high-throughput resequencing array for the detection of pathogenic mutations in osteogenesis imperfecta.

Authors:  Yao Wang; Yazhou Cui; Xiaoyan Zhou; Jinxiang Han
Journal:  PLoS One       Date:  2015-03-05       Impact factor: 3.240

Review 6.  Is p53 Involved in Tissue-Specific Insulin Resistance Formation?

Authors:  Justyna Strycharz; Jozef Drzewoski; Janusz Szemraj; Agnieszka Sliwinska
Journal:  Oxid Med Cell Longev       Date:  2017-01-17       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.